Role of FcγRIIIA (CD16) in IVIg-mediated anti-inflammatory function

Journal of Clinical Immunology

Volumn 34, Issue SUPPL. 1, 2014, Pages

  Ben Mkaddem, Sanae ^a,b,c   Aloulou, Meryem ^a,b,c,e   Benhamou, Marc ^a,b,c   Monteiro, Renato C ^a,b,c,d  

^a CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Fc receptor; Immunotherapy; Inflammation; ITAM; IVIg

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; MULTIPROTEIN COMPLEX; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASE SHP 1;

ANIMAL; AUTOIMMUNE DISEASES; CALCIUM SIGNALING; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; METABOLISM; OXIDATIVE STRESS; PHAGOCYTOSIS; PROCEDURES; PROTEIN MOTIF; SIGNAL TRANSDUCTION;

AMINO ACID MOTIFS; ANIMALS; AUTOIMMUNE DISEASES; CALCIUM SIGNALING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; INFLAMMATION; MULTIPROTEIN COMPLEXES; OXIDATIVE STRESS; PHAGOCYTOSIS; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTORS, IGG; SIGNAL TRANSDUCTION;

EID: 84905163957     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-014-0031-6     Document Type: Article

References (27)

1. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747-55.
2. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27:233-45. (Pubitemid 46790823)
3. Crow AR, Song S, Siragam V, Lazarus AH. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer. 2006;47:710-3. (Pubitemid 44360037)
4. Bussel JB. Another interaction of the FcR systemwith IVIG. Thromb Haemost. 2002;88:890-1. (Pubitemid 36018771)
5. Anthony RM, Nimmerjahn F. The role of differential IgG glycosylation in the interaction of antibodies with FcgammaRs in vivo. Curr Opin Organ Transplant. 2011;16:7-14.
6. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475:110-3.
7. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513-33. (Pubitemid 351600384)
8. Tackenberg B, Nimmerjahn F, Lunemann JD. Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. J Clin Immunol. 2010;30 Suppl 1:S65-9.
9. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002;2:580-92. (Pubitemid 37328733)
10. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov. 2012;11:311-31.
11. Nimmerjahn F, Ravetch JV. FcgammaRs in health and disease. Curr Top Microbiol Immunol. 2011;350:105-25.
12. Willcocks LC, Smith KG, Clatworthy MR. Low-affinity Fcgamma receptors, autoimmunity and infection. Expert Rev Mol Med. 2009;11:e24.
13. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10:328-43.
14. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994;76:519-29. (Pubitemid 24064172)
15. Lanier LL. Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell. 1998;92:705-7. (Pubitemid 28155309)
16. Vivier E, Daeron M. Immunoreceptor tyrosine-based inhibition motifs. Immunol Today. 1997;18:286-91. (Pubitemid 27261448)
17. Montaudouin C, Anson M, Hao Y, Duncker SV, Fernandez T, Gaudin E, et al. Quorumsensing contributes to activated IgM-secreting B cell homeostasis. J Immunol. 2013;190:106-14.
18. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13:176-89.
19. Leontyev D, Katsman Y, Branch DR. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcgamma receptor for the amelioration of experimental ITP. Blood. 2012;119:5261-4.
20. Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffie C, et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity. 2005;22:31-42. (Pubitemid 40143449)
21. Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. Immunol Rev. 2009;232:59-71.
22. Kanamaru Y, Pfirsch S, Aloulou M, Vrtovsnik F, Essig M, Loirat C, et al. Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation. J Immunol. 2008;180:2669-78.
23. Aloulou M, Ben Mkaddem S, Biarnes-Pelicot M, Boussetta T, Souchet H, Rossato E, et al. IgG1 and IVIg induce inhibitory ITAM signaling through FcgammaRIII controlling inflammatory responses. Blood. 2012;119:3084-96.
24. Pfirsch-Maisonnas S, Aloulou M, Xu T, Claver J, Kanamaru Y, Tiwari M, et al. Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized "inhibisome" clusters. Sci Signal. 2011;4:ra24.
25. Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev. 2008;224:70-84.
26. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 2008;29:608-15.
27. Pinheiro da Silva F, Aloulou M, Skurnik D, Benhamou M, Andremont A, Velasco IT, et al. CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat Med. 2007;13:1368-74. (Pubitemid 350073597)